Research
Metabolic adaptation
Metabolic therapies like tirzepatide can reduce weight and improve OSA severity.
Incorporating metabolic therapies may enhance treatment strategies for patients with obesity and OSA.
StrongSupportsmedium confidence
Metabolic therapies, including the dual GIP/GLP-1 receptor agonist tirzepatide, have demonstrated substantial weight reduction and improvement in OSA severity.
Why this rating
The claim is based on the reported outcomes of a specific therapeutic intervention.
Source
The Obesity–OSA–Arrhythmia Axis: Pathophysiological Mechanisms and Translational Therapeutic Targets
Fulvio Cacciapuoti et al. · Life · 2026
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →